Explore

Trendline Trendline
Moonlight Therapeutics Launches Phase I Trial for Peanut Allergy Treatment MOON101

Moonlight Therapeutics Launches Phase I Trial for Peanut Allergy Treatment MOON101

Moonlight Therapeutics Launches Phase I Trial for Peanut Allergy Treatment MOON101
Rapid Read Rapid Read
Penn Medicine Explores CAR-T Therapy for Kidney Failure Treatment

Penn Medicine Explores CAR-T Therapy for Kidney Failure Treatment

Researchers at Penn Medicine are investigating a new application for CAR-T therapy, traditionally used in cancer treatment, to aid patients with kidney failure. CAR-T therapy involves modifying a patient's T cells to better recognize and attack cancer cells. This revolutionary approach has significantly impacted cancer treatment, and now, Penn Medicine's clinical trial aims to explore its potential benefits for kidney failure patients. The trial is in its early stages, and researchers are optimistic about the therapy's ability to address the underlying causes of kidney failure, potentially offering a new treatment avenue for patients who have limited options.
Rapid Read Rapid Read
Study Finds GLP-1 Drugs May Reduce Breast Cancer Risk by 30%

Study Finds GLP-1 Drugs May Reduce Breast Cancer Risk by 30%

A study from the University of Pennsylvania's Perelman School of Medicine has found that women taking GLP-1 medications, commonly used for weight loss, are 30% less likely to develop breast cancer. The analysis involved over 110,000 women aged 45 to 80, revealing that these drugs, while not originally designed for cancer therapy, affect pathways associated with cancer development. The findings suggest potential for GLP-1 drugs as preventive treatments for high-risk women, although further clinical trials are needed to confirm their efficacy in cancer prevention.
Rapid Read Rapid Read
Nephrodite's Holly System Selected for FDA's TAP to Enhance Dialysis Development

Nephrodite's Holly System Selected for FDA's TAP to Enhance Dialysis Development

Nephrodite, Inc., a medical device company, has announced that its Holly implantable continuous dialysis system has been selected to participate in the U.S. Food and Drug Administration's (FDA) Total Product Life Cycle Advisory Program (TAP). This program is designed to accelerate the development and patient access for medical devices addressing critical unmet healthcare needs. The Holly system aims to provide a continuous renal replacement therapy for patients with end-stage kidney disease, offering an alternative to the traditional three-times-weekly clinic-based dialysis. The selection into TAP follows Nephrodite's receipt of the FDA Breakthrough Device Designation in late 2025. The company is preparing for Good Laboratory Practice studies and regulatory submissions to pave the way for early feasibility trials.
Trendline Trendline
ZetrOZ Systems Expands Partnerships to Enhance Access to Evidence-Based Healthcare

ZetrOZ Systems Expands Partnerships to Enhance Access to Evidence-Based Healthcare

ZetrOZ Systems Expands Partnerships to Enhance Access to Evidence-Based Healthcare
Rapid Read Rapid Read
mRNA Vaccine for Melanoma Shows Significant Efficacy in Preventing Recurrence

mRNA Vaccine for Melanoma Shows Significant Efficacy in Preventing Recurrence

A recent study has shown that a personalized mRNA vaccine, developed by Moderna in collaboration with Merck, is highly effective in preventing the recurrence of melanoma when used alongside the immunotherapy drug Keytruda. The trial, which included 157 patients from the U.S. and Australia, demonstrated that the combination therapy reduced the risk of cancer recurrence by 49% over five years. The vaccine is tailored to each patient's tumor, using mRNA technology to train the immune system to recognize and attack specific neoantigens associated with the cancer. This approach has shown promising results, with 68.8% of patients remaining cancer-free after five years, compared to 49.1% who received only Keytruda.
Rapid Read Rapid Read
Personalized mRNA Vaccine Shows Promise in Reducing Melanoma Recurrence

Personalized mRNA Vaccine Shows Promise in Reducing Melanoma Recurrence

A clinical trial has demonstrated the potential of a personalized mRNA vaccine in reducing the recurrence of melanoma. Conducted by researchers at NYU Langone Health, the trial involved 157 patients in Australia and the U.S. who had undergone surgery to remove their tumors. The study combined the mRNA vaccine with Keytruda, an immunotherapy drug, and showed that 68.8% of patients remained cancer-free after five years, compared to 49.1% who received Keytruda alone. The results, presented at the American Society of Clinical Oncology conference, highlight the vaccine's ability to train T cells to recognize and target specific neoantigens, enhancing the immune system's response to cancer.
Rapid Read Rapid Read
Experimental Drug Shows Promise in Extending Survival for Pancreatic Cancer Patients

Experimental Drug Shows Promise in Extending Survival for Pancreatic Cancer Patients

An experimental drug, daraxonrasib, has shown promising results in a Phase 3 clinical trial for patients with metastatic pancreatic cancer. The trial, which enrolled 500 patients, revealed that those treated with daraxonrasib had a median overall survival of 13.2 months, compared to 6.7 months for those receiving chemotherapy. The drug, designed to block RAS proteins, reduced the risk of death by 60%. These findings were presented at the American Society of Clinical Oncology annual meeting and published in the New England Journal of Medicine.
Rapid Read Rapid Read
NYU Langone Health Study Shows Cancer Vaccine Reduces Melanoma Recurrence by 49%

NYU Langone Health Study Shows Cancer Vaccine Reduces Melanoma Recurrence by 49%

A study led by NYU Langone Health and its Perlmutter Cancer Center has demonstrated that a combination of a vaccine, intismeran, and the immunotherapy drug pembrolizumab (Keytruda) can significantly reduce the risk of melanoma recurrence and death. The phase 2b trial, known as KEYNOTE-942, involved 107 patients who had undergone melanoma surgery. The results, presented at the 2026 annual meeting of the American Society of Clinical Oncology, showed that the combination therapy reduced the risk of cancer recurrence or death by 49% compared to the standard treatment of pembrolizumab alone. Additionally, the combination therapy reduced the risk of distant metastasis by 59%. The study highlights the potential of mRNA vaccines like intismeran in enhancing the effectiveness of immunotherapy for cancers with high mutation rates.
Rapid Read Rapid Read
NYU Langone Health Study Shows mRNA Vaccine Reduces Melanoma Recurrence by 49%

NYU Langone Health Study Shows mRNA Vaccine Reduces Melanoma Recurrence by 49%

A recent study conducted by NYU Langone Health and its Perlmutter Cancer Center has demonstrated that a combination of an mRNA-based vaccine, intismeran, and the immunotherapy drug pembrolizumab significantly reduces the risk of melanoma recurrence and death. The study involved 107 patients who had undergone melanoma surgery and were randomly selected to receive the combination therapy. Results showed a 49% reduction in the risk of cancer recurrence or death compared to a control group receiving only pembrolizumab. The study, known as KEYNOTE-942, was presented at the American Society of Clinical Oncology's annual meeting and published in the Journal of Clinical Oncology. The vaccine works by teaching the immune system to recognize and attack cancer cells, utilizing T cells to target specific neoantigens produced by melanoma cells.
Trendline Trendline
Revolution Medicines' Daraxonrasib Shows Promise in Pancreatic Cancer Treatment

Revolution Medicines' Daraxonrasib Shows Promise in Pancreatic Cancer Treatment

Revolution Medicines' Daraxonrasib Shows Promise in Pancreatic Cancer Treatment
Trendline Trendline
Bluejay Diagnostics Partners with Argonaut to Enhance U.S. Manufacturing for Critical-Care Tests

Bluejay Diagnostics Partners with Argonaut to Enhance U.S. Manufacturing for Critical-Care Tests

Bluejay Diagnostics Partners with Argonaut to Enhance U.S. Manufacturing for Critical-Care Tests